Bio-Techne (NASDAQ:TECH) Price Target Cut to $62.00 by Analysts at Wells Fargo & Company

Bio-Techne (NASDAQ:TECH) had its target price decreased by Wells Fargo & Company from $76.00 to $62.00 in a research note issued to investors on Thursday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biotechnology company’s stock.

TECH has been the subject of a number of other research reports. Citigroup reaffirmed a “buy” rating and set a $80.00 target price (up from $70.00) on shares of Bio-Techne in a research note on Wednesday, February 4th. Robert W. Baird set a $49.00 target price on shares of Bio-Techne in a research note on Thursday. Evercore set a $50.00 target price on shares of Bio-Techne in a research note on Thursday. Weiss Ratings downgraded shares of Bio-Techne from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Bio-Techne in a research note on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bio-Techne currently has an average rating of “Moderate Buy” and a consensus price target of $66.77.

Bio-Techne Trading Up 7.4%

NASDAQ:TECH opened at $50.91 on Thursday. The company has a 50-day moving average price of $54.41 and a 200-day moving average price of $59.54. Bio-Techne has a 12 month low of $45.12 and a 12 month high of $72.16. The company has a current ratio of 4.49, a quick ratio of 3.08 and a debt-to-equity ratio of 0.10. The stock has a market cap of $7.97 billion, a price-to-earnings ratio of 73.78, a P/E/G ratio of 3.12 and a beta of 1.41.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.02). Bio-Techne had a net margin of 9.05% and a return on equity of 13.57%. The business had revenue of $311.42 million for the quarter, compared to analysts’ expectations of $316.11 million. During the same period last year, the business earned $0.56 earnings per share. The company’s revenue was down 1.5% on a year-over-year basis. Equities analysts predict that Bio-Techne will post 1.73 EPS for the current year.

Bio-Techne Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Monday, May 18th will be issued a $0.08 dividend. The ex-dividend date of this dividend is Monday, May 18th. This represents a $0.32 annualized dividend and a yield of 0.6%. Bio-Techne’s payout ratio is 46.38%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Impax Asset Management Group plc bought a new stake in shares of Bio-Techne in the fourth quarter worth approximately $11,468,000. Caprock Group LLC bought a new stake in shares of Bio-Techne in the third quarter worth approximately $1,710,000. Madison Asset Management LLC bought a new stake in shares of Bio-Techne in the third quarter worth approximately $41,425,000. Hollow Brook Wealth Management LLC grew its stake in shares of Bio-Techne by 69.7% in the third quarter. Hollow Brook Wealth Management LLC now owns 174,677 shares of the biotechnology company’s stock worth $9,717,000 after acquiring an additional 71,739 shares during the period. Finally, Pembroke Management LTD grew its stake in shares of Bio-Techne by 10.9% in the third quarter. Pembroke Management LTD now owns 376,977 shares of the biotechnology company’s stock worth $20,971,000 after acquiring an additional 37,189 shares during the period. 98.95% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Bio-Techne

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Company is targeting ~100 basis points of margin expansion for Q4 while expecting organic growth to be approximately flat — investors may view cost/margin progress as a path to improved profitability. Q4 guidance article
• Positive Sentiment: Board declared a quarterly dividend of $0.08/share (payable May 29; ex-div May 18) — a modest income signal that can support investor sentiment. Dividend release
• Positive Sentiment: Company highlighted strong growth pockets in the quarter (mid-teens in Spatial Biology, ~50% growth in GMP proteins excluding fast‑track orders, mid-single-digit in proteomic instruments, continued double-digit growth from large pharma) — these growth vectors could underpin recovery if sustained. Q3 results
• Neutral Sentiment: Major sell‑side firms cut price targets but kept constructive ratings — Citigroup lowered its PT to $70 (still a Buy) and Wells Fargo trimmed to $62 (still Overweight). That reduces upside expectations but keeps analyst support. Citigroup note Wells Fargo note
• Negative Sentiment: Fiscal Q3 results disappointed: adjusted EPS $0.53 vs. ~$0.55 consensus and revenue $311.4M below estimates (~$316M), with reported and organic revenue down ~2% YoY — top‑line softness drove the initial selloff. Reuters coverage Earnings summary
• Negative Sentiment: Management cited demand headwinds (U.S. academic funding cuts) and timing of large GMP/commercial shipments and prior-year fast-track orders as reasons for the shortfall — these are external and timing risks that could keep near-term growth uneven. Headwinds explained

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.